Wednesday, July 8, 2026

Patent intelligence · US

US 9919051

Liquid formulation comprising GM-CSF neutralizing compound

granted A61KA61K2039/505A61K39/395A61K39/3955
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 12
Applicant portfolio 1,436
Patent details — US 9919051
Jurisdiction
US
Status
granted
Grant date
Mar 20, 2018
Expiration
Mar 15, 2038
Applicant
TAKEDA GMBH
Claims
23
CPC classes
A61K, A61K2039/505, A61K39/395, A61K39/3955
View on Google Patents ↗

Quick answer

US 9919051 (Liquid formulation comprising GM-CSF neutralizing compound) is held by TAKEDA GMBH. Status: granted. Granted Mar 20, 2018. Expires Mar 15, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
TAKEDA GMBH
Grant date
Expiration
Claims
23
CPC classes
A61K, A61K2039/505, A61K39/395, A61K39/3955, A61K39/39591, A61K47/183

More from TAKEDA GMBH

Related pharmaceutical patents in our USPTO index.

  1. US 12428403

    N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists

    Takeda Pharmaceutical Company Limited · Expires Sep 25, 2045

    granted
  2. US 12421188

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  3. US 12419890

    Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  4. US 12415866

    Monoclonal antibody inhibitor of Factor XIIa

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  5. US 12415782

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  6. US 12409210

    CNS delivery of therapeutic agents

    Takeda Pharmaceutical Company Limited · Expires Sep 4, 2045

    granted
  7. US 12404237

    Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted
  8. US 12403154

    Administration of sting agonist and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted

Frequently asked questions

What is US patent 9919051?

US 9919051 (Liquid formulation comprising GM-CSF neutralizing compound) is held by TAKEDA GMBH. Status: granted. Granted Mar 20, 2018. Expires Mar 15, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9919051?

TAKEDA GMBH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.

When does US 9919051 expire?

Our index shows an expiration date of Mar 15, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.